nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—PTGS1—Sulfasalazine—ankylosing spondylitis	0.182	0.343	CbGbCtD
Irbesartan—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0561	0.106	CbGbCtD
Irbesartan—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0523	0.0987	CbGbCtD
Irbesartan—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0425	0.0802	CbGbCtD
Irbesartan—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0365	0.0688	CbGbCtD
Irbesartan—CYP3A4—Betamethasone—ankylosing spondylitis	0.0365	0.0688	CbGbCtD
Irbesartan—CYP3A4—Prednisolone—ankylosing spondylitis	0.036	0.0679	CbGbCtD
Irbesartan—CYP3A4—Prednisone—ankylosing spondylitis	0.034	0.0641	CbGbCtD
Irbesartan—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0334	0.063	CbGbCtD
Irbesartan—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0212	0.04	CbGbCtD
Irbesartan—JUN—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.00478	0.0528	CbGpPWpGaD
Irbesartan—EDNRA—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.00456	0.0503	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—CREG1—ankylosing spondylitis	0.00423	0.0466	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.00226	0.025	CbGpPWpGaD
Irbesartan—JUN—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.00226	0.025	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.00218	0.024	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.00215	0.0238	CbGpPWpGaD
Irbesartan—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.00187	0.0206	CbGpPWpGaD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00184	0.0203	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00178	0.0196	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.00174	0.0192	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—RUNX3—ankylosing spondylitis	0.00164	0.0181	CbGpPWpGaD
Irbesartan—JUN—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.00163	0.018	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL17A—ankylosing spondylitis	0.00162	0.0179	CbGpPWpGaD
Irbesartan—JUN—CD40/CD40L signaling—CD40LG—ankylosing spondylitis	0.00155	0.0171	CbGpPWpGaD
Irbesartan—PTGS1—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.00151	0.0167	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL12B—ankylosing spondylitis	0.00151	0.0167	CbGpPWpGaD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—IL1A—ankylosing spondylitis	0.00137	0.0152	CbGpPWpGaD
Irbesartan—JUN—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.00134	0.105	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.00134	0.105	CbGdCrCtD
Irbesartan—JUN—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00133	0.0147	CbGpPWpGaD
Irbesartan—JUN—Betamethasone—Dexamethasone—ankylosing spondylitis	0.00132	0.104	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Betamethasone—ankylosing spondylitis	0.00132	0.104	CbGdCrCtD
Irbesartan—JUN—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.0013	0.0143	CbGpPWpGaD
Irbesartan—JUN—Betamethasone—Triamcinolone—ankylosing spondylitis	0.00129	0.101	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.00129	0.101	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Prednisone—ankylosing spondylitis	0.00123	0.0961	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisone—ankylosing spondylitis	0.00123	0.0961	CbGdCrCtD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.00122	0.0134	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.0012	0.0133	CbGpPWpGaD
Irbesartan—JUN—Dexamethasone—Prednisolone—ankylosing spondylitis	0.0012	0.0938	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisolone—ankylosing spondylitis	0.0012	0.0938	CbGdCrCtD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.00119	0.0131	CbGpPWpGaD
Irbesartan—JUN—BCR signaling pathway—CD79A—ankylosing spondylitis	0.00115	0.0127	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL1A—ankylosing spondylitis	0.00111	0.0122	CbGpPWpGaD
Irbesartan—JUN—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.00111	0.0122	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL10—ankylosing spondylitis	0.0011	0.0122	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.0011	0.0122	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.00109	0.0121	CbGpPWpGaD
Irbesartan—JUN—IL6-mediated signaling events—CRP—ankylosing spondylitis	0.00105	0.0116	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.00105	0.0116	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000973	0.0107	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000969	0.0107	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000919	0.0101	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL10—ankylosing spondylitis	0.000908	0.01	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.000858	0.00947	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000839	0.00926	CbGpPWpGaD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000815	0.009	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—IL10—ankylosing spondylitis	0.000808	0.00892	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	0.000801	0.00883	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.000747	0.00825	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000718	0.00792	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000698	0.00771	CbGpPWpGaD
Irbesartan—PTGS1—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000685	0.00756	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000672	0.00741	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000669	0.00738	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL1A—ankylosing spondylitis	0.000661	0.00729	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—IL1A—ankylosing spondylitis	0.000661	0.00729	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00064	0.00706	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—ankylosing spondylitis	0.000606	0.00668	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.0006	0.00662	CbGpPWpGaD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.000578	0.00638	CbGpPWpGaD
Irbesartan—JUN—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.000555	0.00612	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000548	0.00605	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000545	0.00602	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000542	0.00598	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000532	0.00587	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000527	0.00582	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	0.00052	0.00574	CbGpPWpGaD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—TNF—ankylosing spondylitis	0.00052	0.00574	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.000499	0.00551	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000484	0.00534	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000481	0.00531	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000478	0.00528	CbGpPWpGaD
Irbesartan—JUN—Immune System—KIR3DL1—ankylosing spondylitis	0.000477	0.00527	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.00047	0.00518	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000454	0.005	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000453	0.00499	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000444	0.0049	CbGpPWpGaD
Irbesartan—Angiopathy—Prednisone—ankylosing spondylitis	0.000443	0.00121	CcSEcCtD
Irbesartan—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.000442	0.00121	CcSEcCtD
Irbesartan—Immune system disorder—Prednisone—ankylosing spondylitis	0.000441	0.0012	CcSEcCtD
Irbesartan—Malaise—Dexamethasone—ankylosing spondylitis	0.00044	0.0012	CcSEcCtD
Irbesartan—Malaise—Betamethasone—ankylosing spondylitis	0.00044	0.0012	CcSEcCtD
Irbesartan—Oedema—Triamcinolone—ankylosing spondylitis	0.000439	0.0012	CcSEcCtD
Irbesartan—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000439	0.0012	CcSEcCtD
Irbesartan—Vertigo—Dexamethasone—ankylosing spondylitis	0.000438	0.0012	CcSEcCtD
Irbesartan—Vertigo—Betamethasone—ankylosing spondylitis	0.000438	0.0012	CcSEcCtD
Irbesartan—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000438	0.0012	CcSEcCtD
Irbesartan—Syncope—Dexamethasone—ankylosing spondylitis	0.000438	0.00119	CcSEcCtD
Irbesartan—Syncope—Betamethasone—ankylosing spondylitis	0.000438	0.00119	CcSEcCtD
Irbesartan—Arrhythmia—Prednisone—ankylosing spondylitis	0.000436	0.00119	CcSEcCtD
Irbesartan—Infection—Triamcinolone—ankylosing spondylitis	0.000436	0.00119	CcSEcCtD
Irbesartan—Infection—Methylprednisolone—ankylosing spondylitis	0.000435	0.00119	CcSEcCtD
Irbesartan—Shock—Triamcinolone—ankylosing spondylitis	0.000432	0.00118	CcSEcCtD
Irbesartan—Shock—Methylprednisolone—ankylosing spondylitis	0.000431	0.00118	CcSEcCtD
Irbesartan—JUN—Innate Immune System—CARD9—ankylosing spondylitis	0.00043	0.00475	CbGpPWpGaD
Irbesartan—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.00043	0.00117	CcSEcCtD
Irbesartan—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000429	0.00117	CcSEcCtD
Irbesartan—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000429	0.00117	CcSEcCtD
Irbesartan—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000429	0.00117	CcSEcCtD
Irbesartan—Epistaxis—Methotrexate—ankylosing spondylitis	0.000429	0.00117	CcSEcCtD
Irbesartan—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000429	0.00117	CcSEcCtD
Irbesartan—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000428	0.00117	CcSEcCtD
Irbesartan—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000427	0.00117	CcSEcCtD
Irbesartan—JUN—TGF-beta Receptor Signaling—TNF—ankylosing spondylitis	0.000426	0.0047	CbGpPWpGaD
Irbesartan—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000425	0.00116	CcSEcCtD
Irbesartan—Malnutrition—Prednisone—ankylosing spondylitis	0.000425	0.00116	CcSEcCtD
Irbesartan—Erythema—Prednisone—ankylosing spondylitis	0.000425	0.00116	CcSEcCtD
Irbesartan—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000424	0.00116	CcSEcCtD
Irbesartan—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000424	0.00116	CcSEcCtD
Irbesartan—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000423	0.00116	CcSEcCtD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000423	0.00467	CbGpPWpGaD
Irbesartan—Hypertension—Dexamethasone—ankylosing spondylitis	0.000421	0.00115	CcSEcCtD
Irbesartan—Hypertension—Betamethasone—ankylosing spondylitis	0.000421	0.00115	CcSEcCtD
Irbesartan—AGTR1—Allograft Rejection—TNF—ankylosing spondylitis	0.00042	0.00464	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000418	0.00461	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—IL1A—ankylosing spondylitis	0.000418	0.00461	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000417	0.00461	CbGpPWpGaD
Irbesartan—Myalgia—Dexamethasone—ankylosing spondylitis	0.000415	0.00113	CcSEcCtD
Irbesartan—Myalgia—Betamethasone—ankylosing spondylitis	0.000415	0.00113	CcSEcCtD
Irbesartan—Anxiety—Betamethasone—ankylosing spondylitis	0.000414	0.00113	CcSEcCtD
Irbesartan—Anxiety—Dexamethasone—ankylosing spondylitis	0.000414	0.00113	CcSEcCtD
Irbesartan—Discomfort—Betamethasone—ankylosing spondylitis	0.00041	0.00112	CcSEcCtD
Irbesartan—Discomfort—Dexamethasone—ankylosing spondylitis	0.00041	0.00112	CcSEcCtD
Irbesartan—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000409	0.00112	CcSEcCtD
Irbesartan—Pain—Prednisolone—ankylosing spondylitis	0.000408	0.00111	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—ankylosing spondylitis	0.000408	0.00111	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000405	0.0011	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000403	0.0011	CcSEcCtD
Irbesartan—Vision blurred—Prednisone—ankylosing spondylitis	0.0004	0.00109	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—ankylosing spondylitis	0.0004	0.00109	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.0004	0.00109	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000399	0.00109	CcSEcCtD
Irbesartan—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000398	0.00109	CcSEcCtD
Irbesartan—Oedema—Betamethasone—ankylosing spondylitis	0.000398	0.00109	CcSEcCtD
Irbesartan—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000398	0.00109	CcSEcCtD
Irbesartan—Oedema—Dexamethasone—ankylosing spondylitis	0.000398	0.00109	CcSEcCtD
Irbesartan—Infection—Dexamethasone—ankylosing spondylitis	0.000396	0.00108	CcSEcCtD
Irbesartan—Infection—Betamethasone—ankylosing spondylitis	0.000396	0.00108	CcSEcCtD
Irbesartan—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000394	0.00108	CcSEcCtD
Irbesartan—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000394	0.00108	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000393	0.00107	CcSEcCtD
Irbesartan—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000393	0.00107	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—ankylosing spondylitis	0.000393	0.00107	CcSEcCtD
Irbesartan—Anaemia—Prednisone—ankylosing spondylitis	0.000393	0.00107	CcSEcCtD
Irbesartan—Shock—Betamethasone—ankylosing spondylitis	0.000392	0.00107	CcSEcCtD
Irbesartan—Shock—Dexamethasone—ankylosing spondylitis	0.000392	0.00107	CcSEcCtD
Irbesartan—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000391	0.00107	CcSEcCtD
Irbesartan—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000391	0.00107	CcSEcCtD
Irbesartan—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000391	0.00107	CcSEcCtD
Irbesartan—Agitation—Prednisone—ankylosing spondylitis	0.00039	0.00107	CcSEcCtD
Irbesartan—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.00039	0.00106	CcSEcCtD
Irbesartan—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.00039	0.00106	CcSEcCtD
Irbesartan—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000389	0.00106	CcSEcCtD
Irbesartan—Tachycardia—Betamethasone—ankylosing spondylitis	0.000389	0.00106	CcSEcCtD
Irbesartan—Angioedema—Prednisone—ankylosing spondylitis	0.000388	0.00106	CcSEcCtD
Irbesartan—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000386	0.00105	CcSEcCtD
Irbesartan—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000385	0.00105	CcSEcCtD
Irbesartan—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000385	0.00105	CcSEcCtD
Irbesartan—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000385	0.00105	CcSEcCtD
Irbesartan—Malaise—Prednisone—ankylosing spondylitis	0.000383	0.00105	CcSEcCtD
Irbesartan—Vertigo—Prednisone—ankylosing spondylitis	0.000382	0.00104	CcSEcCtD
Irbesartan—Syncope—Prednisone—ankylosing spondylitis	0.000381	0.00104	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—ankylosing spondylitis	0.00038	0.00104	CcSEcCtD
Irbesartan—Anorexia—Dexamethasone—ankylosing spondylitis	0.00038	0.00104	CcSEcCtD
Irbesartan—Anorexia—Betamethasone—ankylosing spondylitis	0.00038	0.00104	CcSEcCtD
Irbesartan—Urticaria—Prednisolone—ankylosing spondylitis	0.000379	0.00103	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000379	0.00103	CcSEcCtD
Irbesartan—Fatigue—Triamcinolone—ankylosing spondylitis	0.000378	0.00103	CcSEcCtD
Irbesartan—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000378	0.00103	CcSEcCtD
Irbesartan—Pain—Triamcinolone—ankylosing spondylitis	0.000375	0.00102	CcSEcCtD
Irbesartan—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000373	0.00102	CcSEcCtD
Irbesartan—Hypotension—Betamethasone—ankylosing spondylitis	0.000372	0.00102	CcSEcCtD
Irbesartan—Hypotension—Dexamethasone—ankylosing spondylitis	0.000372	0.00102	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—ankylosing spondylitis	0.00037	0.00101	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000368	0.00101	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000368	0.001	CcSEcCtD
Irbesartan—Hypertension—Prednisone—ankylosing spondylitis	0.000367	0.001	CcSEcCtD
Irbesartan—Chills—Methotrexate—ankylosing spondylitis	0.000366	0.000999	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000363	0.00099	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000363	0.00099	CcSEcCtD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000362	0.004	CbGpPWpGaD
Irbesartan—Arthralgia—Prednisone—ankylosing spondylitis	0.000362	0.000987	CcSEcCtD
Irbesartan—Myalgia—Prednisone—ankylosing spondylitis	0.000362	0.000987	CcSEcCtD
Irbesartan—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000362	0.000987	CcSEcCtD
Irbesartan—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000361	0.000985	CcSEcCtD
Irbesartan—Anxiety—Prednisone—ankylosing spondylitis	0.000361	0.000984	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000359	0.00098	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000358	0.000977	CcSEcCtD
Irbesartan—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000358	0.000976	CcSEcCtD
Irbesartan—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000358	0.000976	CcSEcCtD
Irbesartan—Discomfort—Prednisone—ankylosing spondylitis	0.000357	0.000975	CcSEcCtD
Irbesartan—Erythema—Methotrexate—ankylosing spondylitis	0.000355	0.000969	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—ankylosing spondylitis	0.000355	0.000969	CcSEcCtD
Irbesartan—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000352	0.00096	CcSEcCtD
Irbesartan—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000351	0.000957	CcSEcCtD
Irbesartan—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000351	0.000957	CcSEcCtD
Irbesartan—Urticaria—Triamcinolone—ankylosing spondylitis	0.000349	0.000951	CcSEcCtD
Irbesartan—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000348	0.000949	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000348	0.000949	CcSEcCtD
Irbesartan—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000347	0.000947	CcSEcCtD
Irbesartan—Oedema—Prednisone—ankylosing spondylitis	0.000347	0.000946	CcSEcCtD
Irbesartan—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000347	0.000946	CcSEcCtD
Irbesartan—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000346	0.000945	CcSEcCtD
Irbesartan—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000346	0.000945	CcSEcCtD
Irbesartan—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000346	0.000945	CcSEcCtD
Irbesartan—Infection—Prednisone—ankylosing spondylitis	0.000345	0.00094	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000344	0.000938	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000344	0.000938	CcSEcCtD
Irbesartan—Fatigue—Dexamethasone—ankylosing spondylitis	0.000343	0.000937	CcSEcCtD
Irbesartan—Fatigue—Betamethasone—ankylosing spondylitis	0.000343	0.000937	CcSEcCtD
Irbesartan—Shock—Prednisone—ankylosing spondylitis	0.000341	0.000931	CcSEcCtD
Irbesartan—Pain—Dexamethasone—ankylosing spondylitis	0.000341	0.000929	CcSEcCtD
Irbesartan—Pain—Betamethasone—ankylosing spondylitis	0.000341	0.000929	CcSEcCtD
Irbesartan—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00034	0.000928	CcSEcCtD
Irbesartan—Tachycardia—Prednisone—ankylosing spondylitis	0.000338	0.000924	CcSEcCtD
Irbesartan—Skin disorder—Prednisone—ankylosing spondylitis	0.000337	0.000919	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000335	0.000915	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—ankylosing spondylitis	0.000335	0.000913	CcSEcCtD
Irbesartan—Anorexia—Prednisone—ankylosing spondylitis	0.000331	0.000902	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000329	0.000899	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—ankylosing spondylitis	0.000328	0.000896	CcSEcCtD
Irbesartan—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000328	0.000896	CcSEcCtD
Irbesartan—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000328	0.000896	CcSEcCtD
Irbesartan—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000326	0.000889	CcSEcCtD
Irbesartan—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000326	0.000889	CcSEcCtD
Irbesartan—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000323	0.000882	CcSEcCtD
Irbesartan—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000323	0.00088	CcSEcCtD
Irbesartan—Malaise—Methotrexate—ankylosing spondylitis	0.00032	0.000874	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—ankylosing spondylitis	0.000319	0.000871	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—ankylosing spondylitis	0.000318	0.000867	CcSEcCtD
Irbesartan—Urticaria—Dexamethasone—ankylosing spondylitis	0.000316	0.000863	CcSEcCtD
Irbesartan—Urticaria—Betamethasone—ankylosing spondylitis	0.000316	0.000863	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000316	0.000862	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000316	0.00349	CbGpPWpGaD
Irbesartan—Dizziness—Prednisolone—ankylosing spondylitis	0.000316	0.000861	CcSEcCtD
Irbesartan—Asthenia—Triamcinolone—ankylosing spondylitis	0.000315	0.000859	CcSEcCtD
Irbesartan—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000315	0.000859	CcSEcCtD
Irbesartan—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000315	0.000859	CcSEcCtD
Irbesartan—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000315	0.000859	CcSEcCtD
Irbesartan—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000315	0.000859	CcSEcCtD
Irbesartan—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000314	0.000857	CcSEcCtD
Irbesartan—Paraesthesia—Prednisone—ankylosing spondylitis	0.000311	0.00085	CcSEcCtD
Irbesartan—Pruritus—Triamcinolone—ankylosing spondylitis	0.000311	0.000847	CcSEcCtD
Irbesartan—Cough—Methotrexate—ankylosing spondylitis	0.00031	0.000846	CcSEcCtD
Irbesartan—Pruritus—Methylprednisolone—ankylosing spondylitis	0.00031	0.000845	CcSEcCtD
Irbesartan—Dyspepsia—Prednisone—ankylosing spondylitis	0.000305	0.000833	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—ankylosing spondylitis	0.000302	0.000825	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—ankylosing spondylitis	0.000302	0.000825	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—ankylosing spondylitis	0.000302	0.000825	CcSEcCtD
Irbesartan—Decreased appetite—Prednisone—ankylosing spondylitis	0.000301	0.000823	CcSEcCtD
Irbesartan—Rash—Prednisolone—ankylosing spondylitis	0.000301	0.000821	CcSEcCtD
Irbesartan—Dermatitis—Prednisolone—ankylosing spondylitis	0.000301	0.00082	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000301	0.00332	CbGpPWpGaD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.0003	0.000819	CcSEcCtD
Irbesartan—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.0003	0.000818	CcSEcCtD
Irbesartan—Fatigue—Prednisone—ankylosing spondylitis	0.000299	0.000816	CcSEcCtD
Irbesartan—Headache—Prednisolone—ankylosing spondylitis	0.000299	0.000816	CcSEcCtD
Irbesartan—JUN—Apoptosis—TNF—ankylosing spondylitis	0.000299	0.0033	CbGpPWpGaD
Irbesartan—Discomfort—Methotrexate—ankylosing spondylitis	0.000299	0.000815	CcSEcCtD
Irbesartan—Constipation—Prednisone—ankylosing spondylitis	0.000297	0.000809	CcSEcCtD
Irbesartan—Dizziness—Triamcinolone—ankylosing spondylitis	0.00029	0.000792	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.00029	0.000791	CcSEcCtD
Irbesartan—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00029	0.00079	CcSEcCtD
Irbesartan—JUN—Immune System—IL1R2—ankylosing spondylitis	0.000289	0.00319	CbGpPWpGaD
Irbesartan—Infection—Methotrexate—ankylosing spondylitis	0.000288	0.000786	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000286	0.00078	CcSEcCtD
Irbesartan—Asthenia—Betamethasone—ankylosing spondylitis	0.000286	0.00078	CcSEcCtD
Irbesartan—Asthenia—Dexamethasone—ankylosing spondylitis	0.000286	0.00078	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000284	0.000776	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000284	0.000774	CcSEcCtD
Irbesartan—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000284	0.000774	CcSEcCtD
Irbesartan—Nausea—Prednisolone—ankylosing spondylitis	0.000283	0.000774	CcSEcCtD
Irbesartan—Pruritus—Betamethasone—ankylosing spondylitis	0.000282	0.000769	CcSEcCtD
Irbesartan—Pruritus—Dexamethasone—ankylosing spondylitis	0.000282	0.000769	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—ankylosing spondylitis	0.000282	0.000768	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.00028	0.000765	CcSEcCtD
Irbesartan—Vomiting—Triamcinolone—ankylosing spondylitis	0.000279	0.000762	CcSEcCtD
Irbesartan—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000278	0.00076	CcSEcCtD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	0.000278	0.00307	CbGpPWpGaD
Irbesartan—Rash—Triamcinolone—ankylosing spondylitis	0.000277	0.000755	CcSEcCtD
Irbesartan—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000276	0.000754	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—ankylosing spondylitis	0.000276	0.000754	CcSEcCtD
Irbesartan—Rash—Methylprednisolone—ankylosing spondylitis	0.000276	0.000753	CcSEcCtD
Irbesartan—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000276	0.000753	CcSEcCtD
Irbesartan—Urticaria—Prednisone—ankylosing spondylitis	0.000276	0.000752	CcSEcCtD
Irbesartan—Headache—Triamcinolone—ankylosing spondylitis	0.000275	0.00075	CcSEcCtD
Irbesartan—Headache—Methylprednisolone—ankylosing spondylitis	0.000274	0.000749	CcSEcCtD
Irbesartan—Body temperature increased—Prednisone—ankylosing spondylitis	0.000274	0.000748	CcSEcCtD
Irbesartan—Abdominal pain—Prednisone—ankylosing spondylitis	0.000274	0.000748	CcSEcCtD
Irbesartan—JUN—Immune System—ERAP1—ankylosing spondylitis	0.000274	0.00302	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000273	0.00301	CbGpPWpGaD
Irbesartan—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000272	0.000744	CcSEcCtD
Irbesartan—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000272	0.000744	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—ankylosing spondylitis	0.000271	0.000739	CcSEcCtD
Irbesartan—JUN—Innate Immune System—HLA-C—ankylosing spondylitis	0.00027	0.00298	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000264	0.000721	CcSEcCtD
Irbesartan—Dizziness—Betamethasone—ankylosing spondylitis	0.000263	0.000719	CcSEcCtD
Irbesartan—Dizziness—Dexamethasone—ankylosing spondylitis	0.000263	0.000719	CcSEcCtD
Irbesartan—Nausea—Triamcinolone—ankylosing spondylitis	0.000261	0.000711	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—ankylosing spondylitis	0.00026	0.00071	CcSEcCtD
Irbesartan—Nausea—Methylprednisolone—ankylosing spondylitis	0.00026	0.00071	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000258	0.000705	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—ankylosing spondylitis	0.000258	0.000703	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000256	0.00282	CbGpPWpGaD
Irbesartan—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000256	0.000697	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000255	0.000696	CcSEcCtD
Irbesartan—Vomiting—Betamethasone—ankylosing spondylitis	0.000253	0.000691	CcSEcCtD
Irbesartan—Vomiting—Dexamethasone—ankylosing spondylitis	0.000253	0.000691	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000252	0.000688	CcSEcCtD
Irbesartan—Rash—Dexamethasone—ankylosing spondylitis	0.000251	0.000685	CcSEcCtD
Irbesartan—Rash—Betamethasone—ankylosing spondylitis	0.000251	0.000685	CcSEcCtD
Irbesartan—Dermatitis—Betamethasone—ankylosing spondylitis	0.000251	0.000685	CcSEcCtD
Irbesartan—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000251	0.000685	CcSEcCtD
Irbesartan—JUN—Immune System—CARD9—ankylosing spondylitis	0.000251	0.00277	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.00025	0.000683	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—ankylosing spondylitis	0.00025	0.000682	CcSEcCtD
Irbesartan—Headache—Dexamethasone—ankylosing spondylitis	0.000249	0.000681	CcSEcCtD
Irbesartan—Headache—Betamethasone—ankylosing spondylitis	0.000249	0.000681	CcSEcCtD
Irbesartan—Asthenia—Prednisone—ankylosing spondylitis	0.000249	0.000679	CcSEcCtD
Irbesartan—Pain—Methotrexate—ankylosing spondylitis	0.000248	0.000676	CcSEcCtD
Irbesartan—Pruritus—Prednisone—ankylosing spondylitis	0.000245	0.00067	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000239	0.000652	CcSEcCtD
Irbesartan—Diarrhoea—Prednisone—ankylosing spondylitis	0.000237	0.000648	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000237	0.000647	CcSEcCtD
Irbesartan—Nausea—Dexamethasone—ankylosing spondylitis	0.000237	0.000646	CcSEcCtD
Irbesartan—Nausea—Betamethasone—ankylosing spondylitis	0.000237	0.000646	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000236	0.0026	CbGpPWpGaD
Irbesartan—Urticaria—Methotrexate—ankylosing spondylitis	0.00023	0.000628	CcSEcCtD
Irbesartan—Dizziness—Prednisone—ankylosing spondylitis	0.000229	0.000626	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000229	0.000625	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000229	0.000625	CcSEcCtD
Irbesartan—Vomiting—Prednisone—ankylosing spondylitis	0.00022	0.000602	CcSEcCtD
Irbesartan—Rash—Prednisone—ankylosing spondylitis	0.000219	0.000597	CcSEcCtD
Irbesartan—Dermatitis—Prednisone—ankylosing spondylitis	0.000218	0.000596	CcSEcCtD
Irbesartan—Headache—Prednisone—ankylosing spondylitis	0.000217	0.000593	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000214	0.00236	CbGpPWpGaD
Irbesartan—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000214	0.000583	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—ankylosing spondylitis	0.000208	0.000567	CcSEcCtD
Irbesartan—Nausea—Prednisone—ankylosing spondylitis	0.000206	0.000562	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—ankylosing spondylitis	0.000205	0.00056	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—B3GNT2—ankylosing spondylitis	0.000204	0.00225	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000201	0.00222	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.0002	0.0022	CbGpPWpGaD
Irbesartan—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000198	0.000541	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000194	0.00214	CbGpPWpGaD
Irbesartan—Dizziness—Methotrexate—ankylosing spondylitis	0.000192	0.000523	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—ankylosing spondylitis	0.000184	0.000503	CcSEcCtD
Irbesartan—Rash—Methotrexate—ankylosing spondylitis	0.000183	0.000499	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—ankylosing spondylitis	0.000183	0.000498	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000182	0.00201	CbGpPWpGaD
Irbesartan—Headache—Methotrexate—ankylosing spondylitis	0.000182	0.000496	CcSEcCtD
Irbesartan—Nausea—Methotrexate—ankylosing spondylitis	0.000172	0.00047	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000172	0.00189	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000161	0.00178	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HLA-B—ankylosing spondylitis	0.00016	0.00176	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-C—ankylosing spondylitis	0.000157	0.00174	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000155	0.00171	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000153	0.00168	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000152	0.00167	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000152	0.00167	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CRP—ankylosing spondylitis	0.000141	0.00156	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1RN—ankylosing spondylitis	0.000137	0.00151	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—TLR4—ankylosing spondylitis	0.000135	0.00149	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000127	0.0014	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD79A—ankylosing spondylitis	0.00012	0.00132	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—B3GNT2—ankylosing spondylitis	0.000115	0.00127	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP3—ankylosing spondylitis	0.000115	0.00127	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1A—ankylosing spondylitis	9.84e-05	0.00109	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD40LG—ankylosing spondylitis	9.79e-05	0.00108	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTGER4—ankylosing spondylitis	9.45e-05	0.00104	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-B—ankylosing spondylitis	9.31e-05	0.00103	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP3—ankylosing spondylitis	9.01e-05	0.000994	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-A—ankylosing spondylitis	8.63e-05	0.000952	CbGpPWpGaD
Irbesartan—JUN—Immune System—CRP—ankylosing spondylitis	8.23e-05	0.000908	CbGpPWpGaD
Irbesartan—JUN—Immune System—TLR4—ankylosing spondylitis	7.89e-05	0.000871	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	7.43e-05	0.00082	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP3—ankylosing spondylitis	6.73e-05	0.000743	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	6.1e-05	0.000673	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	6.05e-05	0.000667	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	5.17e-05	0.00057	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	3.99e-05	0.00044	CbGpPWpGaD
